The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.
News
Secretion of multiple hormones, high morning cortisol levels, higher tumor grade, and diabetes are all significantly associated with a worse prognosis for people with ectopic Cushing’s syndrome (ECS) caused by a neuroendocrine tumor, a new study found. The study, “Multiple hormone secretion may indicate…
Undiagnosed tumors on the adrenal glands — called adrenal incidentalomas, because they are found by chance — may be more prevalent than previously thought and also may be linked to an increased risk of type 2 diabetes, a new study has found. The study, “Adrenal incidentalomas…
More than 70% of patients have been enrolled in Strongbridge Biopharma’s Phase 3 LOGICS clinical trial assessing the safety and effectiveness of Recorlev (levoketoconazole) for treating endogenous Cushing’s syndrome, the company announced. Strongbridge anticipates announcing top-line results from the study before the end of this year and plans to…
Fat accumulation in muscles caused by Cushing’s syndrome leads to impaired muscle function and worse physical performance long after patients have achieved remission with normal cortisol levels, findings from a new study show. The study, “Thigh muscle fat infiltration is associated with impaired physical performance despite…
Ectopic ACTH-secreting pituitary adenomas (EAPAs), a rare cause of Cushing’s disease, are more commonly found in women, who also have a poorer prognosis than men with the same condition, a study suggests. Titled “Long-term follow-up for ectopic ACTH-secreting pituitary adenoma in a single tertiary medical…
Recordati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people with endogenous Cushing’s syndrome, the company announced. The decision follows a European Medicines Agency (EMA) committee recommendation in November to approve Isturisa for that…
One year of treatment with under-the-skin Signifor (pasireotide) lessens tumor volume in many Cushing’s disease patients for whom surgery has failed or is not an option, a post-hoc analysis of a Phase 3 clinical trial shows. Signifor was found to normalize urinary cortisol levels and ease…
People diagnosed with Cushing’s disease during childhood may experience lowered pituitary hormones long after receiving surgery, as well as mood and cognitive disorders, a long-term follow-up study shows. The study, “Long-Term Outcome in Patients After Treatment for Cushing’s Disease in Childhood,” was published in the journal PLoS…
A diagnostic technique called bilateral inferior petrosal sinus sampling (BIPSS), which measures the levels of the adrenocorticotropic hormone (ACTH) produced by the pituitary gland, should only be used to diagnose cyclic Cushing’s syndrome patients during periods of cortisol excess, a case report shows. When it…
Recent Posts
- Surgery brings Cushing’s remission to 60% of patients over 20 years: Study
- New Cushing’s disease treatment option reaches Canada with Isturisa
- I’m trying to be more honest about how medical trauma affects me
- CRH test may replace invasive method in diagnosing Cushing’s disease: Study
- Unexpected insulin resistance exposes rare Cushing’s disease diagnosis
- The challenges of managing Cushing’s disease during the postpartum period
- Test may be ‘practical’ alternative for diagnosing Cushing’s in kids
- Man’s aggressive salivary gland cancer triggers Cushing’s syndrome: Report
- FDA rejects relacorilant for Cushing’s-related high blood pressure
- Study supports Isturisa as first-line ectopic Cushing’s treatment